Novo Nordisk AS (XBUL:NOV) EV-to-EBIT : 16.19 (As of May. 28, 2025)

Novo Nordisk AS EV-to-EBIT Chart

Novo Nordisk AS Annual Data
	Trend	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
EV-to-EBIT		Get a 7-Day Free Trial					18.69	28.75	30.42	29.55	22.11

Novo Nordisk AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBIT	Get a 7-Day Free Trial															34.56	38.35	28.65	22.11	15.54

Competitive Comparison of Novo Nordisk AS's EV-to-EBIT

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk AS's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's EV-to-EBIT falls into.

Novo Nordisk AS EV-to-EBIT Calculation

Novo Nordisk AS's EV-to-EBIT for today is calculated as:

Novo Nordisk AS's current Enterprise Value is лв564,008 Mil.
Novo Nordisk AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was лв34,842 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS  (XBUL:NOV) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Novo Nordisk AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Novo Nordisk AS's Enterprise Value for the quarter that ended in Mar. 2025 was лв297,635 Mil.
Novo Nordisk AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was лв34,842 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description